Chronic obstructive pulmonary disease (COPD), a commonpreventable and treatable disease, is characterized by persistentairflow limitation that is usually progressive and associated withan enhanced chronic inflammatory response in the airways andthe lung to noxious particles or gases. Clinical diagnosis of COPDshould be considered in any individual, who has dyspnea, chroniccough, sputum production, and positive history of risk factors.Pharmacologic therapy can reduce COPD symptoms, reducethe frequency and severity of exacerbations, and improve healthstatus and exercise tolerance. After cessation of smoking andlife style modification, bronchodilator therapy is the first step inCOPD treatment. Beside commonly used bronchodilator therapynewly developed bronchodilators started to be preferred. Thesedrugs consist of long-acting beta2 agonist (Indacatarol, Vilanterol,Olodaterol, Abediterol), long acting muscarinic antagonism(Umeclidinium), long-acting beta2 agonist with inhaled steroid(combination of fluticasone furoate and vilanterol), long-actingbeta2 agonist with a long-acting muscarinic antagonist (Fixeddosecombination of indacaterol with glycopyrronium by means ofbreezhaler device).